Eeshal Zulfiqar

Ms. Eeshal Zulfiqar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in JACC: Advances
Verified
Journal Article
Open access
MAMushood Ahmed
Mushood Ahmed
EZEeshal Zulfiqar
Eeshal Zulfiqar
ASAimen Shafiq
Aimen Shafiq
MSMaryam Shahzad
Maryam Shahzad
THTallal Mushtaq Hashmi
Tallal Mushtaq Hashmi
GFGregg C. Fonarow
Gregg C. Fonarow
The prevalence of type 2 diabetes mellitus (T2DM) has increased in the United States, contributing significantly to morbidity and mortality. This study analyzes trends in T2DM-related mortality focusing on demographic and regional disparities. The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was utilized to extract death certificate data for adults aged 25 and older from 1999 to 2023. Age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated. Temporal trends were assessed by calculating the annual percent change using Joinpoint regression analysis. From 1999 to 2023, a total of 2,031,626 deaths were attributed to T2DM in the United States. The AAMR more than doubled from 21.54 per 100,000 in 1999 to 53.95 per 100,000 in 2023 with a pronounced increase between 2018 and 2021 (AAMR: 62.7 in 2021, annual percent change: 16.06%; 95% CI: 11.84-19.66). Males had considerably higher AAMR than females (68.82 vs 42.48 in 2023). Among racial and ethnic groups, Hispanic or Latino populations had the highest AAMR in 2023 (69.69), followed by non-Hispanic Black or African American (65.45), non-Hispanic other populations (53.7), and non-Hispanic White group (49.98). The Western region of the United States showed the highest AAMR (78.29), and rural areas consistently had higher mortality rates compared to urban areas (69.88 vs 55.32 in 2020). From 1999 to 2023, cardiovascular disease accounted for 626,706 deaths among adults with T2DM. T2DM-related mortality has increased substantially over the time in the United States, with a peak observed between 2018 and 2021, emphasizing the need for targeted interventions.

14 December 2023 in International Journal of Surgery
Verified
Journal Article
Open access
ZNZainab Nazir
Zainab Nazir
AHAshna Habib
Ashna Habib
TATooba Ali
Tooba Ali
ASAjeet Singh
Ajeet Singh
EZEeshal Zulfiqar
Eeshal Zulfiqar
MD ARIFUL HAQUEMD ARIFUL HAQUE
MD ARIFUL HAQUE
An abstract is unavailable. This article is available as a PDF only.

15 November 2024 in Medicine
Verified
Journal Article
Open access
MTMuhammad Daoud Tariq
Muhammad Daoud Tariq
HJHritvik Jain
Hritvik Jain
AKAbdul Moiz Khan
Abdul Moiz Khan
SSSyeda Shahnoor
Syeda Shahnoor
PGPriya Mbbs Goyal
Priya Mbbs Goyal
ASAmir Humza Sohail
Amir Humza Sohail
Background: Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) with high mortality rates. While mechanical circulatory support devices like intra-aortic balloon pump (IABP) and Impella are used to manage CS, their comparative effectiveness remains unclear. This meta-analysis aims to evaluate the safety and efficacy of Impella in the treatment of AMI-associated CS. Methods: A comprehensive literature search was performed across PubMed, EMBASE, Google Scholar, SCOPUS, and Web of Science. The primary efficacy endpoint was 6-month all-cause mortality. Secondary efficacy endpoints included 30-day mortality, major bleeding, limb ischemia, sepsis, and left ventricular ejection fraction. Pooled odds ratios (OR) and standardized mean difference (SMD) with 95% confidence intervals (CIs) were calculated using the random-effects model via Revman version 5.4. Statistical significance was determined at P < .05. Results: Four RCTs with a total of 442 patients were included in this meta-analysis. The pooled analysis showed that the odds of 6-month all-cause mortality were significantly lower with Impella compared to standard of care (OR: 0.64, 95% CI: 0.43–0.95; P value: .03). However, 30-day mortality reported no statistically significant difference between the 2 groups (OR: 1.03; 95% CI: 0.43–2.48; P = .95). Our analysis found that the use of impella is associated with a statistically significant increase in the odds of major bleeding (OR: 3.61; 95% CI: 1.14–11.40; P = .03), limb ischemia (OR: 4.91; 95% CI: 1.37–17.59; P = .01), and sepsis (OR: 2.75; 95% CI: 1.25–6.08; P = .01). No statistical significance was found in left ventricular ejection fraction at follow-up between the 2 groups (SMD: −0.35; 95% CI: −0.78 to 0.07; P = .11). Conclusion: Impella significantly reduces 6-month all-cause mortality in patients with CS following AMI compared to standard of care. However, this survival benefit is offset by a substantial increase in major bleeding, limb ischemia, and sepsis risks associated with Impella. Future large scale trials are needed to validate these findings and refine clinical guidelines for the optimal use of Impella in treating CS.

18 November 2024 in International Journal of Surgery
Verified
Journal Article
Open access
MAMushood Ahmed
Mushood Ahmed
AAAreeba Ahsan
Areeba Ahsan
ASAimen Shafiq
Aimen Shafiq
ZNZain Ali Nadeem
Zain Ali Nadeem
FAFariha Mbbs Arif
Fariha Mbbs Arif
FSFarhan Shahi
Farhan Shahi
Background: Surgical aortic valve replacement (SAVR) is the commonly used approach for aortic valve replacement (AVR) in patients with aortic stenosis at low or intermediate surgical risk. However, transcatheter aortic valve replacement (TAVR) has emerged as an alternative to SAVR for AVR. This meta-analysis aims to assess the comparative efficacy and safety of TAVR versus SAVR in low-to-intermediate surgical risk patients by analyzing temporal trends in the outcomes of TAVR and SAVR at various follow-up intervals, providing a more detailed understanding. Methods: A thorough literature search was performed across PubMed/MEDLINE, Embase, and the Cochrane Library from their inception up to May 2024 to identify eligible randomized controlled trials (RCTs). Clinical outcomes were evaluated using a random-effects model to pool risk ratios (RRs) with 95% CIs. Results: A total of 17 studies reporting data at different follow-ups for nine trials were included (n=9092). No statistically significant difference was observed between TAVR and SAVR for reducing all-cause death at 30 days, 1 year, and 2 years but significantly increased risk with TAVR at 5 years or longer follow-up (RR=1.13, 95% CI: 1.03–1.23). However, TAVR was associated with a significantly decreased risk for cardiac death at 1-year follow-up (RR=0.79, 95% CI: 0.64–0.96) and comparable risk for cardiac death at 30 days, 2 years, and 5 years or longer follow-up when compared with SAVR. No statistically significant difference was observed between TAVR and SAVR for reducing the risk of myocardial infarction (MI) at 30 days, 1 year, 2 years, and 5 years or longer follow-up. TAVR was associated with a significantly lower risk of major bleeding events at 30 days (RR=0.38, 95% CI: 0.21–0.67); lower risk of acute kidney injury (AKI) at 30 days (RR=0.38, 95% CI: 0.26–0.54) and 1 year (RR=0.58, 95% CI: 0.41–0.82) and lower risk of new onset or worsening atrial fibrillation (AF) at 30 days (RR=0.25, 95% CI: 0.18–0.34), 1 year (RR=0.26, 95% CI: 0.16–0.41) and 2 years (RR=0.32, 95% CI: 0.20–0.49) when compared with SAVR. However, TAVR was associated with a significantly increased risk of permanent pacemaker implantation (PPI) at 30 days (RR: 2.62, 95% CI: 1.40–4.91), at 1 year (RR: 2.19, 95% CI: 1.24–3.87), at 2 years (RR: 2.74, 95% CI: 1.31–5.71), and beyond 5 years (RR: 1.95, 95% CI: 1.20–3.15). TAVR was also associated with a significantly increased risk of prosthetic valve thrombosis at 2 years (RR=2.70, 95% CI: 1.08–6.71), though no significant association was observed at 30 days, 1 year, or 5 years. Similarly, no significant differences were observed in aortic-valve reintervention rates at 30 days, 2 years, or 5 years, but TAVR showed a significantly increased risk at 1 year (RR=1.98, 95% CI: 1.21–3.24). TAVR was associated with a significantly increased risk of major vascular complications at 30 days (RR=2.37, 95% CI: 1.38–4.04) and a significantly increased risk of TIA at 2 years (RR: 1.43, 95% CI: 1.02–2.00, I 2=0%). The risk of hospitalizations was comparable between the groups. Conclusion: TAVR and SAVR demonstrated comparable rates of all-cause death up to 2 years of follow-up. However, at 5 years or longer follow-up, TAVR was associated with a higher risk of all-cause death. While TAVR showed certain procedural advantages, such as a lower risk of major bleeding, AKI, and new-onset or worsening AF, the choice between TAVR and SAVR in patients with low or intermediate surgical risk should consider long-term outcomes, with SAVR potentially being more favorable due to better survival observed on longer follow-up durations.

3 January 2025 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
AMAreesha Mansoor
Areesha Mansoor
MSMaryam Shahzad
Maryam Shahzad
EZEeshal Zulfiqar
Eeshal Zulfiqar
MAMuneeba Ahsan
Muneeba Ahsan
RARimsha Adnan
Rimsha Adnan
AMAbdullah Malikzai
Abdullah Malikzai
Anti-seizure medications (ASMs) are specific types of anticonvulsants used to treat epileptic seizures. However, several studies have shown an association between ASMs and an increased risk of hematological disorders, such as thrombocytopenia, aplastic anemia, and platelet function disorders leading to prolonged bleeding times. This review explores the existing literature on this topic, investigating a wide variety of ASMs, ranging from first-generation medications to newer ones. A comprehensive search was conducted on all the currently approved ASMs using PubMed and Google Scholar: review articles, clinical trials, meta-analysis, observational studies, case reports, and relevant animal studies were identified. We extracted 15 ASMs including valproic acid (VPA), carbamazepine, phenytoin, phenobarbital, diazepam, clonazepam, lamotrigine, levetiracetam, oxcarbazepine, felbamate, topiramate, pregabalin, lacosamide, cannabidiol (CBD), and perampanel that contain considerable literature regarding different coagulopathies. An in-depth review of over 140 studies revealed a robust association between ASM-induced changes and the onset of bleeding disorders via several different mechanisms. Polytherapy, the use of multiple ASMs, also emerged as a significant risk factor for the development of coagulopathies. This review highlights the potential link between ASMs and bleeding disorders, emphasizing the importance of considering this risk during treatment planning. By understanding these associations, healthcare providers can optimize patient outcomes and minimize bleeding risks. Additionally, this review identifies the need for further research to bridge current knowledge gaps in clinical pharmacology related to ASMs and bleeding disorders.

19 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
INIbrahim Ali Nasser
Ibrahim Ali Nasser
SAshereen asghar
shereen asghar
LMLaraib Masud
Laraib Masud
MHMuhammad Ali Hafeez
Muhammad Ali Hafeez
SHSonia Hurjkaliani
Sonia Hurjkaliani
RARaheel Ahmed
Raheel Ahmed
Background and Objectives: Growing evidence suggests a strong relationship between hypertension and cancer, which can increase the risk of poor prognosis. However, data regarding mortality related to cancer and hypertension are limited. Our study aims to analyze the mortality trends related to cancer and hypertension in the United States from 1999 to 2023. Materials and Methods: A retrospective observational analysis was conducted using mortality data for the adult U.S. population from 1999 to 2023, retrieved from the CDC WONDER database using death certificates. Age-adjusted mortality rates (AAMRs) were calculated, and annual percentage changes (APCs) were analyzed using JoinPoint Regression. Results: From 1999 to 2023, a total of 1,406,107 deaths related to cancer and hypertension were recorded in the United States. The AAMR increased from 12.59 in 1999 to 35.49 in 2023. Males had a higher mortality rate compared to women throughout the study period (AAMR; 30.3 vs. 20.4). Non-Hispanic (NH) Black Americans, or African Americans had the highest mortality rates, followed by NH white, Hispanic or Latino groups, and other NH groups. The highest AAMR was observed in the South, followed by the Midwest, the Northeast, and the West. Rural areas had higher mortality rates compared to urban areas. Conclusions: Cancer- and hypertension-related mortality rates have consistently increased in the United States from 1999 to 2023, particularly affecting males, NH Black Americans, the southern region, and rural areas. The trends highlight the need for targeted prevention, including early screening, lifestyle changes, and treatment adherence.